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Rapid Arc. 4) PF test during RapidArc with intentional errors. 
5) Accurate control of dose rate and gantry speed during 
RapidArc delivery. 6) Accurate control of leaf speed during 
RapidArc delivery. These RapidArc QA plans were loaded on 
Machine and analysed using EPID portal dosimetry system. 
Results and Discussion: Taking DMLC dosimetry, we measured 
meter reading at gantry angles 0°, 180°, 90° and 270° for a 
4x10 cm DMLC field with a 0.5 cm slit, and the effect of 
gravity on leaf position and linac head  showed maximum 
percentage deviation of -0.96% (± 2%). PF test at stationary 
gantry angles 0°, 180°, 90° and 270°, we evaluated the 
maximum DMLC positional shift of 0.5mm (± 1 mm). PF test 
during RapidArc (arc 179º-187º) has inspected the effect of 
gantry rotation on the MLC position, the result showed a 
maximum positional shift of -0.2 mm (± 1 mm). PF test during 
RapidArc with intentional errors have demonstrated that the 
test (3) can detect sub-millimetre errors during RapidArc. 
Accurate control of dose rate and gantry speed during 
RapidArc delivery has been examined by using 7 combinations 
of dose-rate, gantry range and gantry speed to give equal 
dose to seven 1.8 cm strips in a RapidArc field. When 
normalised to open field at same position (to exclude the 
beam profile influence), the dose of seven strips showed 
good result, with maximum mean deviation of 1.90% (< 2%). 
Accurate control of leaf speed during RapidArc delivery has 
been analysed by using 4 combinations of leaf speed (1.6, 
2.4, 0.8 and 0.4 cm/s) and dose-rate to give equal dose to 
four strips in a RapidArc field. When normalised to 
corresponding open field, the dose of four strips showed good 
result, with a maximum mean deviation of 1.74% (< 2%). All 
the test results showed good agreement with manufacture 
and published literature stated tolerance values (written in 
bracket in front of each result).The RapidArc commissioning 
data has also obtained an approval from Atomic Energy 
Regulatory Board (AERB), Mumbai, India. 
Conclusion: The dosimetric verification of DMLC movement, 
variable dose rates and gantry speed provides confidence 
over precision and accuracy during RapidArc delivery. These 
test are aimed only for commissioning and dosimetric 
verification of RapidArc enabled linac, and not for patient 
specific QA. 
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Purpose: Boost fields (A small field with isocentre blocked 
and less beam weightage) are routinely used in three 
dimensional conformal radiotherapy (3D-CRT) treatment 
plans of oesophagus, head and neck etc for enhancing PTV 
coverage. Challenges for using boost fields are associated 
with accuracy of treatment planning system (TPS) to 
calculate dose distribution, normalisation and monitor units 
(MUs) as isocentre is blocked so dosimetric verification of 
boost field is essential. The purpose of this study was to 
measure two things; first contribution of ‘Boost fields’ doses 
to the target isocentre, second doses to the region of 
interest of boost field and finally compare the dosimetrically 
measured data with TPS calculated data. 
Materials and Methods: Eclipse TPS (Version 8.6, Varian) was 
used for all boost fields 3D-CRT treatment plans in this study. 
The solid water phantom with dimension (25cmx25mx5cm), 
(25cmx25mx2cm) and (25cmx25mx5cm) respectively was 
used. The 0.65cc ionisation chamber was used for dosimetry 
in this study with SAD (source axis distance) setup. In boost 
fields study, five treatment plans of oesophagus case each 
having two plans with 6MV and 15MV and each plan having 
two boost fields (one is LPO boost field and other is RPO 
boost field) were performed. The contribution of boost field 
doses to the target isocentre for both 6MV and 15MV plans 
were measured with the help of ionisation chamber and also 
calculated in treatment planning system. The doses to the 
region of interest of boost field at 5cm depth in phantom 
were measured with help of thermoluminescence detector 
(TLD-100) and also calculated in treatment planning system 
for both 6MV and 15MV plans. Finally the measured and 
calculated data was compared. 
Results: Mean percentage variation between TPS calculated 
and ionisation chamber measured boost field doses to the 
target isocentre was 1.53% (SD 4.12) for 6MV and 4.13% (SD 
6.81) for 15MV. Maximum Percentage variation for this was 
6% and 12% for 6MV and 15MV respectively. Mean percentage 
variation between TPS calculated and TLDs measured boost 
field doses of region of interest of boost field was -1.22% (SD 
2.03) for 6MV and -0.4% (SD 2.84) for 15MV. Maximum 
percentage variation for this was 4% and 5% for 6MV and 
15MV respectively. TLDs were in good agreement with TPS. 
Results shows that contribution of boost field doses to the 
target isocentre for both 6MV and 15MV were less than 1cGy.  
Conclusion: Dosimetric verification of MUs delivered by boost 
fields is essential to verify the accuracy of TPS algorithms. 
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Purpose: In radionuclide therapy today mostly β−-labelled 
radiopharmaceuticals are used which irradiate the body 
internally with time-dependent dose-rate and can cause DNA 
double strand breaks (DSBs).  
The formation of a DNA DSB in nuclear chromatin results in 
the rapid phosphorylation of the histone variant gamma-
H2AX. DSBs also recruit the damage sensor 53BP1 to the 
chromatin surrounding the DSBs, which leads to 53BP1 and 
gamma-H2AX co-localization. By immunofluorescence 
staining with gamma-H2AX and 53BP1 antibodies those 
biomarkers can be addressed by microscopically visible foci.  
The number of foci per cell represent a quantitative 
biomarker for DNA double strand breaks and hence for 
radiation exposure and radiation effects. Presently, there are 
only few studies, which are studying the on-set and decay of 
DSBs after radionuclide therapy.  
The aim of our study was, therefore, to generate an in-vitro 
calibration curve for quantifying the dose-response of the 
number of radiation induced foci (RIF) after internal 
irradiation of blood with β−-emitters, and to describe 
comprehensively the dose-dependent time course of the DSB 
on-set and repair in lymphocytes of radiation treatment-
naive patients after radiopeptide therapy with 177Lu and 
radioiodine therapy with 131I. 
Material and Methods: For the in-vitro calibration with 131I 
and 177Lu blood samples were drawn from volunteers. 
Different activity concentrations were added, the samples 
were incubated for 1h to achieve absorbed doses up to 
100mGy, and the number of RIF/cell was determined.  
The patient studies addressed the relationship between the 
absorbed dose to the blood and the number and temporal 
behavior of radiation-induced DNA double strand breaks 
(RIF/cell) in multiple peripheral blood samples under 
radiopeptide therapy (16 patients) and under radioiodine 
therapy (20 patients).  
Results: The in-vitro study shows that the number of RIF/cell 
is linearly dependent of the absorbed dose, similar to what 
has been observed after external irradiation. 
In patients, the average number of RIF/cell showed a linear 
dose-response relationship within the first hours after 
administration of the radiopharmaceutical. Later time points 
were characterized by a diminishing number of radiation-
S38  ICTR-PHE 2016 
 
induced foci which was in accordance with the progression of 
DNA repair and the declining dose rates. The absorbed dose 
in most patients treated with 131I exceeded 20mGy in the first 
hour, and in these patients, the on-set of a fast repair 
component was observed. 
Conclusions: With the experimental results and model 
calculations presented in this work, for the first time a dose-
response relationship and a description of the time course of 
the in-vitro and in-vivo damage response after internal 
irradiation of β−-emitters could be established. 
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Purpose: In proton therapy, two major beam delivery 
techniques are used which are referenced as active and 
passive delivery strategies. In latter case, an effective dose 
distribution into tumor volume is created by pencil beam 
extracted from the accelerator exit window. To do this aim, 
the modulation is performed to produce two uniform beam 
profiles: 1) along with beam trajectory and 2) in lateral 
direction vertical to beam direction. The first dose profile 
cover tumor volume in target depth against beam direction 
and the second lateral profile include tumor volume, 
transversely. Several passive devices are utilized to create 
depth dose profile known as Spread-Out Bragg Peak (SOBP) 
and transverse dose profiles. In proton therapy, the final 
purpose is to produce a three dimensional (3D) homogeneous 
dose distribution onto the tumor volume while minimizing the 
dose to the surrounding healthy tissues around the tumor. 
Relating to moving and deforming targets, the delivery dose 
is not matched with the planned dose. 
Methods: Our goal in this work is to obtain a quantitative 
assessment of three dimensional dose distribution on the 
moving and deforming targets and surrounding normal tissues 
affected by the breathing motion. For this aim, a simulation 
study was performed using Monte Carlo FLUKA code. The 
effect of each of the parameters in a clinical passive beam 
scanning system on radiotherapy dosage was considered. The 
dose deposition from protons was simulated for fields 
designed for the treatment of dynamic, deformed and static 
tumors. 
Results: Dose distribution results of Monte Carlo method 
simulation were compared with the results obtained during 
experimental process at Cyclotron and Radioisotope Center 
(CYRIC) in Tohoku University. Final analyzed results represent 
that the uniformity of dose distribution on all given tumors 
are up to 95% of uniformity that proves a successful dose 
delivery onto tumor as well according to planned dose. The 
results of dose distribution into tumor and surrounding 
healthy tissues around the tumor for static spherical case 
regarding with deformed tumors and moving tumors were 
obtained. Conclusion: In conventional proton therapy a 
significant dose is delivered to the normal tissues in 
comparison with stationary condition without getting any 
strategy to limit ITV region such as motion gated or real-time 
tumor tracking strategies. The accuracy of dose distribution 
increasing with decreasing magnitude of deformation, moving 
and stretching of the tumor. 
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An initial design of a compact, high current Fixed Field 
Alternating Gradient accelerator has been made for the 
direct production of 99mTc and the production of a number of 
therapeutic isotopes that currently available only in limited 
quantities or not at all. These studies indicate that the FFAG 
could in principle accelerate a proton beam of up to 20mA to 
at least 30 MeV and high current alpha beams to a similar 
energy. This presentation will describe the FFAG and show 
what radioisotope yields should be possible. It will also 
outline the next steps in the project. It should be noted that 
the same basic FFAG design is being extended to the energies 
required for cancer therapy with light ion beams.   
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